Jessica Merrill
Senior Editor
Latest From Jessica Merrill
EyePoint Hits New Durability Milestone For Wet AMD Treatment
Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.
Industry Leaderboard Gains And Dips Were Still Marked By COVID-19
Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.
Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.
Novartis Has A New Goal: $2bn Peak Sales Per Product
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
NYC’s Ambition: Be A Premier Biotech Hub
New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.
US FDA Delay For Abecma In Early MM Gives Carvykti Time To Catch Up
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.